Breaking Down Cardiogenic Shock: An Analytical Reflection on the DanGer-SHOCK and ECLS-SHOCK Trials

IF 2.3 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS
Giuseppe Tarantini MD, PhD , Andrea Panza MD , Giulia Lorenzoni PhD , Dario Gregori PhD , Giulia Masiero MD
{"title":"Breaking Down Cardiogenic Shock: An Analytical Reflection on the DanGer-SHOCK and ECLS-SHOCK Trials","authors":"Giuseppe Tarantini MD, PhD ,&nbsp;Andrea Panza MD ,&nbsp;Giulia Lorenzoni PhD ,&nbsp;Dario Gregori PhD ,&nbsp;Giulia Masiero MD","doi":"10.1016/j.amjcard.2024.10.032","DOIUrl":null,"url":null,"abstract":"<div><div>Mechanical circulatory support devices, particularly the microaxial flow pump (mAFP), have gained traction in managing cardiogenic shock in patients with acute myocardial infarction. However, trials like DanGer-SHOCK (Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock) and ECLS-SHOCK (Extracorporeal Life Support in Infarct Related Cardiogenic Shock) have reported differing outcomes, making it challenging to draw definitive conclusions. To explore this further, we conducted a comparative analysis of the 30-day and 6-month mortality rates from the DanGer-SHOCK and ECLS-SHOCK trials, examining differences in patient populations and risk profiles. The goal was to determine whether these differences could explain the conflicting outcomes or if the benefits observed in the DanGer-SHOCK trial were directly attributable to the mAFP strategy. One key finding is that, despite similar control group mortality rates, the intervention group in DanGer-SHOCK demonstrated a notably lower mortality rate at both 30 days and 6 months compared with the ECLS trial, with an absolute difference of approximately 8%. This benefit is not due to inherent risk differences but is instead attributed to the Impella-based strategy. Compared with standard care, mAFP data revealed a 7% mortality reduction at 30 days, which grew to 12.7% at 180 days, highlighting the long-term effectiveness of the mAFP strategy in maintaining hemodynamic stability and improving survival. These results suggest that, in cardiogenic shock management, the DanGer unloading strategy, when combined with percutaneous coronary intervention, plays a significant role in improving long-term survival through early intervention and ventricular unloading, independent of control group factors. Further research is needed to confirm the broader applicability of this approach in different patient populations.</div></div>","PeriodicalId":7705,"journal":{"name":"American Journal of Cardiology","volume":"236 ","pages":"Pages 30-33"},"PeriodicalIF":2.3000,"publicationDate":"2024-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Cardiology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0002914924007720","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Mechanical circulatory support devices, particularly the microaxial flow pump (mAFP), have gained traction in managing cardiogenic shock in patients with acute myocardial infarction. However, trials like DanGer-SHOCK (Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock) and ECLS-SHOCK (Extracorporeal Life Support in Infarct Related Cardiogenic Shock) have reported differing outcomes, making it challenging to draw definitive conclusions. To explore this further, we conducted a comparative analysis of the 30-day and 6-month mortality rates from the DanGer-SHOCK and ECLS-SHOCK trials, examining differences in patient populations and risk profiles. The goal was to determine whether these differences could explain the conflicting outcomes or if the benefits observed in the DanGer-SHOCK trial were directly attributable to the mAFP strategy. One key finding is that, despite similar control group mortality rates, the intervention group in DanGer-SHOCK demonstrated a notably lower mortality rate at both 30 days and 6 months compared with the ECLS trial, with an absolute difference of approximately 8%. This benefit is not due to inherent risk differences but is instead attributed to the Impella-based strategy. Compared with standard care, mAFP data revealed a 7% mortality reduction at 30 days, which grew to 12.7% at 180 days, highlighting the long-term effectiveness of the mAFP strategy in maintaining hemodynamic stability and improving survival. These results suggest that, in cardiogenic shock management, the DanGer unloading strategy, when combined with percutaneous coronary intervention, plays a significant role in improving long-term survival through early intervention and ventricular unloading, independent of control group factors. Further research is needed to confirm the broader applicability of this approach in different patient populations.
打破心源性休克:对 DanGer-SHOCK 和 ECLS-SHOCK 试验的分析反思。
机械循环支持(MCS)设备,尤其是微轴血流泵(mAFP),在管理急性心肌梗死(AMI)患者的心源性休克(CS)方面获得了广泛关注。然而,DanGer-Shock 和 ECLS-Shock 等试验报告的结果各不相同,因此很难得出明确的结论。为了进一步探讨这一问题,我们对 DanGer-Shock 和 ECLS-Shock 试验的 30 天和 6 个月死亡率进行了比较分析,研究了患者人群和风险特征的差异。目的是确定这些差异是否能解释相互矛盾的结果,或者在 DanGer-Shock 试验中观察到的益处是否直接归因于 mAFP 策略。一个重要发现是,尽管对照组死亡率相似,但与 ECLS 试验相比,DanGer-Shock 试验干预组在 30 天和 6 个月内的死亡率都明显较低,绝对差异约为 8%。这种益处不是由于固有的风险差异,而是由于基于 Impella 的策略。与标准护理相比,mAFP 数据显示,30 天的死亡率降低了 7%,180 天的死亡率降低了 12.7%,这突出表明了 mAFP 策略在维持血流动力学稳定和提高存活率方面的长期有效性。这些结果表明,在 CS 管理中,DanGer 卸载策略与经皮冠状动脉介入治疗(PCI)相结合,通过早期介入治疗和心室卸载,在改善长期存活率方面发挥了重要作用,不受对照组因素的影响。要证实这种方法在不同患者群体中的广泛适用性,还需要进一步的研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
American Journal of Cardiology
American Journal of Cardiology 医学-心血管系统
CiteScore
4.00
自引率
3.60%
发文量
698
审稿时长
33 days
期刊介绍: Published 24 times a year, The American Journal of Cardiology® is an independent journal designed for cardiovascular disease specialists and internists with a subspecialty in cardiology throughout the world. AJC is an independent, scientific, peer-reviewed journal of original articles that focus on the practical, clinical approach to the diagnosis and treatment of cardiovascular disease. AJC has one of the fastest acceptance to publication times in Cardiology. Features report on systemic hypertension, methodology, drugs, pacing, arrhythmia, preventive cardiology, congestive heart failure, valvular heart disease, congenital heart disease, and cardiomyopathy. Also included are editorials, readers'' comments, and symposia.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信